文献速递其他结缔组织病

清髓后造血干细胞移植与系统性硬化症分子特征长期正常化

Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long-Term Normalization of Systemic Sclerosis Molecular Signatures.
PubMed 文献 · Arthritis Rheumatol · 2024-04-29

在SCOT随机试验中,比较清髓后造血干细胞移植(HSCT)与12个月静脉环磷酰胺(CYC)对系统性硬化症(SSc)外周血细胞基因表达特征的影响。HSCT组在随机化后38个月和54个月均显示干扰素模块下调、细胞毒性/自然杀伤模块上调,54个月时与健康对照无差异表达模块;CYC组未检测到差异表达模块,且两个时间点仍显示SSc转录特征。

要点

  • HSCT组38个月和54个月均较基线干扰素模块显著下调、细胞毒性/自然杀伤模块上调
  • HSCT组54个月样本与健康对照相比未显示任何差异表达模块,提示免疫重建完成
  • CYC组未检测到差异表达模块,且两个时间点与对照相比仍显示SSc转录特征

核心结论

  • 与观察到的临床获益平行,HSCT导致SSc分子特征持久的长期正常化,免疫重置在HSCT后54个月完成。

研究设计与样本

  • 随机SCOT试验中,对接受HSCT或12个月静脉CYC的参与者,在治疗前基线以及随机化后38个月和54个月进行全外周血细胞转录研究,并与健康对照比较,使用Illumina HT-12芯片。

主要发现

  • 30名参与者(HSCT=19,CYC=11)有38个月样本,26名(HSCT=16,CYC=11)有54个月样本。
  • HSCT组在38个月和54个月访视时,与基线配对比较,观察到干扰素模块显著下调和细胞毒性/自然杀伤模块上调。
  • CYC组未检测到差异表达模块。
  • HSCT组38个月样本与健康对照相比,显示B细胞和浆母细胞模块上调、髓系和炎症模块下调。
  • HSCT组54个月样本与健康对照相比未显示任何差异表达模块;CYC组在两个时间点与对照相比仍显示SSc转录特征。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In the randomized Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial, myeloablation, followed by hematopoietic stem cell transplantation (HSCT), led to the normalization of systemic sclerosis (SSc) peripheral blood cell (PBC) gene expression signature at the 26-month visit. Herein, we examined long-term molecular changes ensuing 54 months after randomization for individuals receiving an HSCT or 12 months of intravenous cyclophosphamide (CYC). METHODS: Global PBC transcript studies were performed in study participants at pretreatment baseline and at 38 months and 54 months after randomization, as well as in healthy controls using Illumina HT-12 arrays. RESULTS: Thirty (HSCT = 19 and CYC = 11) participants had 38-month samples available, and 26 (HSCT = 16 and CYC = 11) had 54-month samples available. In the paired comparison to baseline, a significant down-regulation of interferon modules and an up-regulation of cytotoxic/natural killer module were observed at the 38-month and 54-month visits in the HSCT arm, indicating a long-term normalization of baseline SSc gene expression signature. No differentially expressed modules were detected in the CYC arm. In comparison to samples from healthy controls, 38-month visit samples in the HSCT arm showed an up-regulation of B cell and plasmablast modules and a down-regulation of myeloid and inflammation modules. Importantly, 54-month HSCT samples did not show any differentially expressed modules compared to healthy control samples, suggesting completion of immune reconstitution. Participants in the CYC arm continued to show an SSc transcript signature in comparison to controls at both time points. CONCLUSION: Paralleling the observed clinical benefit, HSCT leads to durable long-term normalization of the molecular signature in SSc, with completion of immune resetting to 54 months after HSCT.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Wareing N, Wang X, Keyes-Elstein L, et al. Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long-Term Normalization of Systemic Sclerosis Molecular Signatures. Arthritis Rheumatol. 2024. PMID: 38497141. doi:10.1002/art.42847

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。